Suryateja Chaturvedula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suryateja Chaturvedula has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Aseem Vashist
Division of Cardiology, University of Connecticut, Farmington, Connecticut; Division of Cardiology, Saint Francis Hospital and Medical Center, Hartford, Connecticut; Division of Cardiology, VACT Healthcare System, West Haven, Connecticut; Frank H. Netter School of Medicine at Quinnipiac School of Medicine, North Haven, Connecticut
2 shared publications - Daniel Diver
Hoffman Heart and Vascular Institute, St. Francis Hospital and Medical Center, Hartford, CT 06105, USA
2 shared publications
Latest Publications
- Open Access
- 9 April 2018
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (4) , 74
Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma
Percutaneous coronary intervention (PCI) with stenting for the treatment of acute coronary syndrome (ACS) is the contemporary standard of care. Such treatment is followed by dual antiplatelet therapy (DAPT) comprising of aspirin and a P2Y12 inhibitor. The efficacy of this therapy has been well established but the optimal duration of DAPT remains elusive, and has thus far attracted a prodigious deal of scientific attention. The decision regarding DAPT duration can be clinically challenging in the modern era with the evolution of newer stents, more potent antiplatelet agents, and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. Major societal guidelines have emphasized comprehensive assessment of ischemic and bleeding risk, in turn recommending individualization of DAPT duration, thus encouraging “shared decision making”. The following review is aimed at critically evaluating the available evidence to help make these crucial clinical decisions regarding duration of DAPT and triple therapy.
- 9 April 2018
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (4) , 74
Open AccessAntiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma
Percutaneous coronary intervention (PCI) with stenting for the treatment of acute coronary syndrome (ACS) is the contemporary standard of care. Such treatment is followed by dual antiplatelet therapy (DAPT) comprising of aspirin and a P2Y12 inhibitor. The efficacy of this therapy has been well established but the optimal duration of DAPT remains elusive, and has thus far attracted a prodigious deal of scientific attention. The decision regarding DAPT duration can be clinically challenging in the modern era with the evolution of newer stents, more potent antiplatelet agents, and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. Major societal guidelines have emphasized comprehensive assessment of ischemic and bleeding risk, in turn recommending individualization of DAPT duration, thus encouraging “shared decision making”. The following review is aimed at critically evaluating the available evidence to help make these crucial clinical decisions regarding duration of DAPT and triple therapy.
- Open Access
- 12 February 2018
- Published by MDPI AG in Preprints.org
Dual Antiplatelet Therapy (DAPT) in Coronary Artery Disease: A Daunting Dilemma
Percutaneous coronary intervention(PCI) with stenting for the treatment of acute coronary syndrome(ACS) is the contemporary standard of care. Such treatment is followed by Dual anti-platelet therapy(DAPT) comprising of aspirin and a P2Y12 inhibitor. The efficacy of this therapy has been well established but the optimal duration of DAPT remains elusive, and has thus far attracted a prodigious deal of scientific attention. Decision regarding DAPT duration can be challenging clinically in the modern era with the evolution of newer stents, more potent antiplatelet agents and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. Major societal guidelines have emphasized comprehensive assessment of ischemic and bleeding risk, in turn recommending individualization of DAPT duration, thus encouraging "shared decision making". The following review is aimed at critically evaluating the available evidence to help make these crucial clinical decisions regarding duration of DAPT and triple therapy.
- 12 February 2018
- Published by MDPI AG in Preprints.org
Open AccessDual Antiplatelet Therapy (DAPT) in Coronary Artery Disease: A Daunting Dilemma
Percutaneous coronary intervention(PCI) with stenting for the treatment of acute coronary syndrome(ACS) is the contemporary standard of care. Such treatment is followed by Dual anti-platelet therapy(DAPT) comprising of aspirin and a P2Y12 inhibitor. The efficacy of this therapy has been well established but the optimal duration of DAPT remains elusive, and has thus far attracted a prodigious deal of scientific attention. Decision regarding DAPT duration can be challenging clinically in the modern era with the evolution of newer stents, more potent antiplatelet agents and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. Major societal guidelines have emphasized comprehensive assessment of ischemic and bleeding risk, in turn recommending individualization of DAPT duration, thus encouraging "shared decision making". The following review is aimed at critically evaluating the available evidence to help make these crucial clinical decisions regarding duration of DAPT and triple therapy.